Eyevensys Partners with Phillips-Medisize and Minnetronix to Produce Gene Therapy Device for Eye Disease


[ad_1]

Eyevensys aims to develop gene therapies to treat some of the most serious and vision-threatening eye diseases, as well as an electro-transfer platform to deliver these DNA-based solutions directly to the ciliary muscle of the eye. ‘eye.

As these gene therapies advance into the final stages of clinical trials, its drug delivery device needs a corresponding upgrade – and the Paris-based company is looking in the United States to plan for this business expansion.

Eyevensys has form separate multi-year strategic partnerships with Phillips-Medisize and Minnetronix Medical to develop the next version of its electrotransfection system. These efforts have already begun, with Phillips-Medisize working on optimizing the design of the ocular device component of the system, which injects the plasmid DNA solution into the eye, while Minnetronix improves the electrical pulse generator powering the system. system.

The US-based manufacturers are taking over from Cisteo Medical and Valotec, both based in France and tasked with rolling out the first edition of the device.

RELATED: Minnetronix Changes Name From Contract Manufacturer To In-House Medical Tech Developer

When combined, the two components of the system deliver gene therapy to the entire eye. Over a 15-second sequence, the pulse generator activates electroporation, temporarily opening cell membranes of ciliary muscle to allow DNA plasmids to enter cells. Once inside the cells, the plasmids essentially turn the eye into a “biousin”, causing it to produce its own therapeutic proteins.

These proteins can then be sent throughout the eye as needed – to the back of the eye and both sides of the retina, as well as to the front of the eye – to treat retinal diseases like wet and dry macular degeneration, glaucoma and more. .

With the help of Phillips-Medisize and Minnetronix, Eyevensys aims to create a new version of the system that is not only easier to use, but can also be widely marketed, as the company’s gene therapies move closer to ‘regulatory approval.

The most advanced to date is Eyevensys therapy to treat non-infectious uveitis, or inflammation of the middle layer of the eye, which can lead to severe vision loss without proper treatment. This tumor necrosis factor protein is in phase 2 clinical studies, the data collected during these trials being used to guide the development of the improved electrotransfection system.

RELATED: Boehringer Ingelheim Fuels Gene Therapy Startup Focused on Eye Disease

Eyevensys formed its two new partnerships shortly after raising more than $ 40 million in a Series B double-tranche financing round. The first round firm in early 2020, when longtime funder Boehringer Ingelheim led the inflow of $ 30 million, with help from new and existing investors Pontifax, Bpifrance, CapDecisif, Inserm Transfert, the Global Health Sciences Fund and Pureos Bioventures.

Then, last month, Eyevensys tacked on An additional $ 12 million in turn expanded Series B-plus. This time around, the funding was led by Korea Investment Partners, which other unidentified existing investors also joined.

[ad_2]

Comments are closed.